Humacyte Inc. (HUMA)
| Bid | 3.74 |
| Market Cap | 482.50M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.34 |
| PE Ratio (ttm) | -2.8 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.77 |
| Volume | 843,055 |
| Avg. Volume (20D) | 4,185,715 |
| Open | 3.87 |
| Previous Close | 3.87 |
| Day's Range | 3.74 - 3.86 |
| 52-Week Range | 2.81 - 9.97 |
| Beta | undefined |
About HUMA
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without i...
Analyst Forecast
According to 8 analyst ratings, the average rating for HUMA stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 273.33% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
23 hours ago · accessnewswire.com
Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMAPHILADELPHIA, PA / ACCESS Newswire / February 20, 2025 / Kehoe Law Firm, P.C. is investigating whether certain officers and directors of Humacyte, Inc. ("Humacyte") (NASDAQ:HUMA) breached their fiduci...
1 month ago · accessnewswire.com
January 17, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against HUMANEW YORK, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities law...
